Pliant Therapeutics pauses BEACON-IPF Phase 2b trial of bexotegrast after DSMB review

PLIANT THERAPEUTICS, INC.

Voluntarily paused enrollment and dosing in BEACON-IPF Phase 2b trial of bexotegrast for idiopathic pulmonary fibrosis (IPF).
Pause follows prespecified data review and recommendations by independent Data Safety Monitoring Board (DSMB).
Patients currently enrolled in the trial will remain and be monitored while data is reviewed; blinding maintained.
Company has informed trial investigators and is in process of informing global regulatory authorities.
No details provided on DSMB rationale; lead asset trial halt likely materially negative for PLRX stock.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.